LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Search Results
Core dementia treatment technology patented at 6 European countries, concurrentl…
2015/07/30
‘CARTISTEM’ shows superb results from 3 year long term tracking clinical trials
2015/07/23
Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe
2015/07/06
‘CARTISTEM’ injection to U.S. clinical trial subject completed
2015/05/29
U.S. ABC News gave intensified coverage on ‘CARTISTEM’
2015/05/20
Participation in Biotec Japan and local publicity activities on CARTISTEM
2015/05/13
The only Korean company invited to North American Rare Medicine conference
2015/04/24
Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed
2015/04/15
Administration of lung disease medicine ‘PNEUMOSTEM’ started in U.S. clinical tr…
2015/03/25
Accumulated Dosage of CARTISTEM Exceeds 2,000 Cases
2015/02/17
“Stem cells and cord blood at one view” Reorganization of MEDIPOST w…
2015/02/04
Quantity of Cord Blood under Custody Exceeds 200,000 Units for the First Time in…
2015/01/27
Previous
1
…
8
9
10
11
12
13
14
Next
Menu